5 completed, 1 enrolling by invitation, 1 recruiting, 1 suspended. 4 Phase 4, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 1, Suspended 1, Terminated 1, Withdrawn 1 |
| Not applicable | 1 | Enrolling by invitation 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Chlorothiazide: new trials by email Literature Review of Chlorothiazide trials Research Report on Chlorothiazide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Metolazone Oral Tablet, Chlorothiazide Injection - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 4 | Terminated | University of Virginia | 5 | 2018-06-01 | 2021-02-16 |
| Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure tolvaptan, Chlorothiazide, Metolazone - Heart Failure | Phase 4 | Completed | Vanderbilt University | 60 | 2016-02-01 | 2019-11-08 |
| Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide), IV Chlorothiazide - Heart Failure | Phase 1 | Completed | Yale University | 458 | 2015-08-31 | 2025-08-17 |
| Combination Diuretic Therapy for Acute Decompensated Heart Failure Furosemide plus Chlorothiazide, Furosemide - Acute Decompensated Heart Failure | Phase 4 | Withdrawn | Ochsner Health System | 2014-05-01 | 2023-05-03 | |
| Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus chlorothiazide - Diabetes Insipidus, Nephrogenic | Completed | National Center for Research Resources (NCRR) | 1995-09-01 | 2005-06-24 | ||
| Treatment of Hypertension chlorothiazide, Rauwolfia alkaloids - Cardiovascular Diseases, Heart Diseases | Phase 3 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1966-04-01 | 2013-11-26 |
Heart Failure (5) · Hypertension (4) · Cardiovascular Diseases (3) · COVID-19 (2) · Coronavirus Infections (2) · Adrenal Insufficiency (1) · Arrhythmias, Cardiac (1) · Attention Deficit Disorder with Hyperactivity (1) · Bronchopulmonary Dysplasia (1) · Cellulitis (1) · Diabetes Insipidus (1) · Diabetes Insipidus, Nephrogenic (1) · Down Syndrome (1) · Edema (1) · Endocrine System Diseases (1)
Duke University (1) · Enhanced Emirates Limited (1) · National Center for Research Resources (NCRR) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · National University of Ireland, Galway, Ireland (1) · Ochsner Health System (1) · University of Utah (1) · University of Virginia (1) · Vanderbilt University (1) · Yale University (1)
United States (6) · Canada (1) · Ireland (1) · United Arab Emirates (1)
Adam P Bress, PharmD, MS (1) · Anthony Damato (1) · Chi Hornik (1) · Christfried Urner (1) · Gary L. Robertson (1) · J. Warbasse (1) · Jeffrey Testani, MD (1) · John Vaillancourt (1) · John William McEvoy, MBBCh MHS (1) · Patrick T Campbell, MD (1) · Richard Thurm (1) · Robert Wells (1) · Stacy Mandras, MD (1) · Zachary L Cox, PharmD (1)
PMID 31838029, PMID 33891615, PMID 36896716, PMID 40938670
R01HL128973 (1)